Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

39 trials with published results (22%)

Research Maturity

96 completed trials (53% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

7.7%

14 terminated out of 181 trials

Success Rate

87.3%

+0.8% vs benchmark

Late-Stage Pipeline

13%

23 trials in Phase 3/4

Results Transparency

41%

39 of 96 completed with results

Key Signals

39 with results87% success14 terminated

Data Visualizations

Phase Distribution

113Total
Not Applicable (42)
Early P 1 (2)
P 1 (14)
P 2 (32)
P 3 (14)
P 4 (9)

Trial Status

Completed96
Recruiting28
Unknown16
Terminated14
Active Not Recruiting13
Withdrawn12

Trial Success Rate

87.3%

Benchmark: 86.5%

Based on 96 completed trials

Clinical Trials (181)

Showing 20 of 20 trials
NCT07027826Not ApplicableRecruiting

The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

NCT06381219Not ApplicableRecruitingPrimary

Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot Trial

NCT05543512Not ApplicableCompletedPrimary

The Immune Directed Individualized Elimination Therapy (iDIET) Study

NCT05774184Phase 2CompletedPrimary

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

NCT05757856Phase 2CompletedPrimary

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

NCT06352073Phase 4Active Not RecruitingPrimary

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

NCT06851559Phase 2RecruitingPrimary

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

NCT06596252Phase 3RecruitingPrimary

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

NCT05583227Phase 3Active Not RecruitingPrimary

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT07506746Recruiting

PRospective Registry of Esophageal Motility

NCT02504853Recruiting

Natural History and Genetics of Food Allergy and Related Conditions

NCT06817213Not ApplicableRecruitingPrimary

Patient-Centered Decision Support for Eosinophilic Esophagitis

NCT05608681Phase 1RecruitingPrimary

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

NCT05199532RecruitingPrimary

Eosinophilic Gastrointestinal Disorders Registry

NCT05309590Active Not RecruitingPrimary

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

NCT06695897RecruitingPrimary

A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

NCT03640975CompletedPrimary

Innate Immunity in Eosinophilic Esophagitis

NCT05606705Not ApplicableCompletedPrimary

A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis

NCT06972147RecruitingPrimary

Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis

NCT05485155Phase 2RecruitingPrimary

Zemaira Eosinophilic Esophagitis Pilot Study

Scroll to load more

Research Network

Activity Timeline